» Articles » PMID: 2190793

Endometriosis 1990. Current Treatment Approaches

Overview
Journal Drugs
Specialty Pharmacology
Date 1990 Apr 1
PMID 2190793
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Endometriosis is an extremely common gynaecological disease, affecting between 1 and 5% of women of reproductive age. Women with endometriosis typically present for medical care with one of more of the following problems: pelvic pain, infertility, or a large adnexal mass (an endometrioma). The primary treatment for an endometrioma is surgical. However, long term postoperative hormone therapy may be necessary to prevent new endometriomas from developing. There is no evidence that hormonal therapy of endometriosis will improve fecundability in women with endometriosis and infertility. Pelvic pain due to endometriosis can be successfully treated with hormonal agents in the majority of patients. Four basic hormonal regimens are currently available for the treatment of endometriosis: (a) danazol; (b) gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); gonadorelin] agonists; (c) progesterones (progestins); and (d) combined estrogens and progesterones. Randomised, controlled, clinical trials suggest that danazol and the GnRH agonists are equally effective in the treatment of endometriosis. However, the side effects caused by danazol and the GnRH agonists are markedly different. Danazol produces androgenic side effects including weight gain, hirsutism, acne, oily skin and deepening of the voice. GnRH agonists produce side effects due to hypoestrogenism, including hot flushes, osteoporosis and dry vagina. The ideal drug regimen for the treatment of endometriosis remains to be developed.

Citing Articles

Androgen Signaling in Uterine Diseases: New Insights and New Targets.

Lv M, Yu J, Huang Y, Ma J, Xiang J, Wang Y Biomolecules. 2022; 12(11).

PMID: 36358974 PMC: 9687413. DOI: 10.3390/biom12111624.


Prospects and Challenges of the Drug Delivery Systems in Endometriosis Pain Management: Experimental and Theoretical Aspects.

Toma B, Socolov R, Popa O, Socolov D, Nica I, Agop M J Immunol Res. 2021; 2021:2727174.

PMID: 34957311 PMC: 8695015. DOI: 10.1155/2021/2727174.


Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis.

Brown J, Crawford T, Allen C, Hopewell S, Prentice A Cochrane Database Syst Rev. 2017; 1:CD004753.

PMID: 28114727 PMC: 6464974. DOI: 10.1002/14651858.CD004753.pub4.


Body size and endometriosis: results from 20 years of follow-up within the Nurses' Health Study II prospective cohort.

Shah D, Correia K, Vitonis A, Missmer S Hum Reprod. 2013; 28(7):1783-92.

PMID: 23674552 PMC: 3685336. DOI: 10.1093/humrep/det120.


Pre and post operative medical therapy for endometriosis surgery.

Yap C, Furness S, Farquhar C Cochrane Database Syst Rev. 2004; (3):CD003678.

PMID: 15266496 PMC: 6984629. DOI: 10.1002/14651858.CD003678.pub2.


References
1.
Janne O, Kauppila A, Kokko E, Lantto T, Ronnberg L, Vihko R . Estrogen and progestin receptors in endometriosis lesions: comparison with endometrial tissue. Am J Obstet Gynecol. 1981; 141(5):562-6. DOI: 10.1016/s0002-9378(15)33278-6. View

2.
Filicori M, Flamigni C . GnRH agonists and antagonists. Current clinical status. Drugs. 1988; 35(1):63-82. DOI: 10.2165/00003495-198835010-00004. View

3.
Henzl M, Corson S, Moghissi K, Buttram V, Berqvist C, Jacobson J . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med. 1988; 318(8):485-9. DOI: 10.1056/NEJM198802253180805. View

4.
Holt Jr J, Keller D . Danazol treatment increases serum enzyme levels. Fertil Steril. 1984; 41(1):70-4. DOI: 10.1016/s0015-0282(16)47544-8. View

5.
Chrisp P, Goa K . Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs. 1990; 39(4):523-51. DOI: 10.2165/00003495-199039040-00005. View